Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTC HIV tests: 42% of at-risk survey respondents said they "likely" would use test-- NEJM.

This article was originally published in The Gray Sheet

Executive Summary

HOME HIV TESTS: 42% OF AT-RISK INDIVIDUALS SURVEYED WOULD "LIKELY" USE the test if it were approved by FDA for over-the-counter use, Kathryn Phillips, PhD, University of California-San Francisco, et al. note in a study published in the May 11 New England Journal of Medicine. The study found that 42% of 2,523 respondents to a national health survey who were deemed to be at risk for HIV said they would be "very or somewhat likely to use home tests" for the virus. Sixty-three percent of this group noted that they had never been tested for HIV, excluding testing for blood donations.

You may also be interested in...

Rx List Price Inflation Penalty Endorsed By US HHS Secretary

Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.

Generics Approvals Will Decline, US FDA Predicts, But Supplement Work May Grow

With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.

US FDA Puts All China Drug Inspections On Hold Due To Coronavirus Outbreak

February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts